1. Introduction {#S6}
===============

The treatment of advanced melanoma has progressed considerably with the introduction of T-cell checkpoint inhibitors, including inhibitors of cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) \[[@R1]--[@R4]\]. An antibody to CTLA-4, ipilimumab, improved the overall survival (OS) of patients with advanced melanoma in two phase III, randomised controlled trials \[[@R1],[@R5]\]. The PD-1 inhibitors nivolumab and pembrolizumab have shown improved progression-free survival (PFS) and OS compared with ipilimumab \[[@R3],[@R4],[@R6]\]; in addition, nivolumab has shown improved PFS and OS compared with chemotherapy \[[@R2]\].

Combination treatment with nivolumab plus ipilimumab has shown considerable efficacy across clinical trials \[[@R4],[@R6]--[@R9]\], including the phase II CheckMate 069 study and the phase III CheckMate 067 study in patients with untreated advanced melanoma, with objective response rates of 59% and 58%, respectively, for the combination and 11% and 19%, respectively, for ipilimumab alone \[[@R4],[@R8]\]. In addition, 2-year OS for the combination compared with ipilimumab alone was 64% versus 54% \[[@R9]\] and 64% versus 45% \[[@R6]\].

The greater efficacy of combined checkpoint inhibitors is accompanied by higher incidence of grade 3 and 4 adverse events (AEs) versus either agent alone. In CheckMate 069, treatment-related grade 3/4 AEs were reported in 54% of patients who received combination and 20% of patients who received ipilimumab alone \[[@R9]\]; for CheckMate 067, the percentages were 55% and 27%, respectively \[[@R4]\]. This toxicity profile might diminish health-related quality of life (HRQoL). Patient-reported outcomes (PROs), such as symptoms, HRQoL, and patient-perceived health status supplement clinical data and are now more important during decision-making in oncology because they provide a holistic understanding of patient experience and treatment effectiveness \[[@R10],[@R11]\]. Ipilimumab monotherapy did not have a significant negative HRQoL impact in patients with stage III or IV melanoma \[[@R12]\], and nivolumab monotherapy maintained baseline HRQoL levels compared with dacarbazine in patients with advanced melanoma \[[@R13]\]. Here we report analyses of HRQoL for patients with advanced melanoma treated with nivolumab plus ipilimumab, nivolumab alone, or ipilimumab alone in CheckMate 067. In addition to the full HRQoL patient population, we examined subgroups including patients with *BRAF* mutation status, patients with a partial or complete response, patients with treatment-related AEs of grade 3 or 4, and patients who discontinued due to any reason and those who discontinued due to an AE.

2. Patients and methods {#S7}
=======================

2.1. Study design {#S8}
-----------------

This study presents 12-month HRQoL data from the 067 CheckMate double-blind, phase III study; study details have been published \[[@R4]\]. Briefly, patients aged ≥ 18 years with histologically confirmed stage III (unresectable) or stage IV melanoma with no prior systemic treatment for advanced disease were randomised 1:1:1 and stratified by programmed cell death ligand 1 (PD-L1) status, *BRAF* status, and metastatic stage. Patients received one of the following by intravenous infusion, with the appropriate placebo: nivolumab 3 mg/kg every 2 weeks (Q2W); nivolumab 1 mg/kg Q3W plus ipilimumab 3 mg/kg Q3W for 4 doses, followed by nivolumab 3 mg/kg Q2W; or ipilimumab 3 mg/kg Q3W for 4 doses. Treatment was continued until disease progression, development of unacceptable toxic events, or withdrawal of consent. Per investigator, patients with clinical benefit and without substantial AEs could be treated beyond progression.

2.2. Assessments {#S9}
----------------

HRQoL was collected, as available, in all randomised patients and assessed at weeks 1 and 5 of each 6-week cycle for the first 6 months and then once every 6 weeks thereafter as well as at two visits in the follow-up period ([Fig. A.1](#SD1){ref-type="supplementary-material"}). Secondary end-point assessment was European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Version 3 \[[@R14],[@R15]\]; European Quality of Life-5 Dimensions (EQ-5D) Summary Index and Visual Analogue Scale (VAS) \[[@R16],[@R17]\] and the Work Productivity and Activity Impairment: General Health (WPAI:GH) were exploratory end-points \[[@R18]\]. WPAI:GH analyses were not included in this report because they only include patients in the workforce and the number of patients was too low for adequate analysis.

2.3. Statistical analyses {#S10}
-------------------------

Analyses were performed on all randomised patients with both a baseline and ≥ 1 post-baseline assessment. Analyses were also performed on subgroups including patients with *BRAF* mutation status, patients with a partial or complete response, and patients with AEs of grade 3 or 4. In addition, follow-up data were analysed for patients who discontinued due to any reason and those who discontinued due to an AE. For each instrument, the questionnaire completion rate was defined as the proportion of patients who completed the questionnaire at the indicated time point using the number of patients in the study at the respective time point as the denominator. It was predetermined that conclusions would only be drawn from time points for which ≥ 30 patients completed assessments.

Continuous data were described using descriptive statistics, and categorical data were summarised using counts and percentages. Mean changes from baseline at each time point were reported and assessed according to minimally important difference (MID) values, with statistical significance assessed at *P* ≤ 0.05. The EORTC QLQ-C30 is a 30-item, self-administered, multidimensional, cancer-specific, HRQoL PRO questionnaire, with a difference of 10 points on a 100-point scale considered clinically meaningful \[[@R19]\]. The EQ-5D-3L descriptive system is composed of the five dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with a utility index score difference of 0.08 considered clinically meaningful; the EQ-5D VAS records the respondent\'s self-rated health on a vertical VAS with a score of 7 considered clinically meaningful \[[@R20]\].

To assess longitudinal changes from baseline within and between each treatment, modelling was conducted using all observed data through week 55 via a mixed-effects model for repeated measures (MMRM), including baseline PRO score and stratification factors as covariates. MMRM can give unbiased estimates with certain missing data contexts and can be more powerful than a two-sample *t*-test \[[@R21]\]. Least squares (LS) means and standard error (SE) as well as LS means difference with 95% confidence interval (CI) were calculated for nivolumab versus ipilimumab and for nivolumab + ipilimumab combination versus ipilimumab alone. Estimates were based on a mixed model with treatment and time point as fixed effects, study day as a random effect, and time point as a repeated measure.

Values were imputed for missing items for the EORTC QLQ-C30 by using values equal to the average of the non-missing items for scales in which at least half of the items were completed. A scale in which fewer than half of the items were completed was treated as missing and, once the instrument was scored, no imputation was used to handle missing data. No adjustment was made for missing data when scoring the EQ-5D index or the EQ-5D VAS and no imputation was used to handle missing data for the longitudinal analysis.

Analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).

3. Results {#S11}
==========

3.1. Baseline characteristics and questionnaire completion rates {#S12}
----------------------------------------------------------------

The study conducted at 137 sites in 21 countries had an enrolment period from June 2013 to March 2014 \[[@R4]\]. Of the 1296 patients enrolled, 945 were randomised: 316 to nivolumab (313 treated), 314 to nivolumab + ipilimumab (313 treated), and 315 to ipilimumab (311 treated). HRQoL outcomes were performed on all 803 randomised patients with both a baseline and at least one post-baseline assessment (HRQoL randomised population; [Table 1](#T1){ref-type="table"}). Baseline demographics and disease characteristics were similar among the treatment groups and to the main study all-randomised-patients group ([Table 1](#T1){ref-type="table"}) \[[@R4]\].

Questionnaires were completed over a maximum of 79 weeks as well as two follow-up visits following treatment discontinuation ([Table 2](#T2){ref-type="table"}). Completion rates for the EORTC QLQ-C30 at baseline plus ≥1 visit were 85.1% for nivolumab, 87.3% for nivolumab + ipilimumab, and 82.2% for ipilimumab. Completion rates for the EQ-5D-3L at baseline plus ≥1 visit were 84.5% for nivolumab, 87.3% for nivolumab + ipilimumab, and 81.9% for ipilimumab. At each time point through week 67, completion rates remained ≥50% for both questionnaires. Of the 383 patients who progressed in the first 4 months, 69 (54%) in the nivolumab group, 38 (46%) in the nivolumab + ipilimumab group, and 97 (56%) in the ipilimumab group had follow-up PRO data. Analysis conclusions were drawn from time points for which ≥30 patients completed assessments. Although overall completion rates for WPAI:GH were similar to EORTC QLQ-C30 and EQ-5D-3L, ranging from 80.6% to 86.3% at baseline, completion rates for individual subsections at baseline were very low, including percentage of work time missed (28.9--30.4%), percentage of impairment while working (21.9--24.0%), and percentage of overall work impairment (21.9--23.7%).

3.2. HRQoL randomised population analyses {#S13}
-----------------------------------------

Changes from baseline for EORTC QLQ-C30 are shown in [Fig. 1A](#F1){ref-type="fig"}. Slight deterioration from baseline started at week 5 and showed an overall trend toward stabilization from week 25. No clinically meaningful changes were observed in any treatment group while on treatment. Clinically meaningful deterioration was observed at week 7 for nivolumab + ipilimumab for role functioning as well as the fatigue and appetite loss symptom scales (data not shown).

Changes from baseline for EQ-5D utility index are shown in [Fig. 1B](#F1){ref-type="fig"} and for EQ-5D VAS in [Fig. 1C](#F1){ref-type="fig"}. No clinically meaningful changes were observed in any group while on treatment in any time point.

3.3. MMRM results for benefit assessment {#S14}
----------------------------------------

Longitudinal modelling was performed using all observed data for patients remaining in the study through week 55 including baseline PRO and stratification factors as covariates. [Table A.1](#SD1){ref-type="supplementary-material"} shows the LS means and SE for nivolumab versus ipilimumab and for nivolumab versus nivolumab + ipilimumab across the longitudinal model through week 55, as well as the difference in LS means between treatment arms with 95% CIs. No clinically meaningful changes were observed based on MID within any treatment arm for EORTC QLQ-C30 or EQ-5D.

3.4. Subgroup analyses {#S15}
----------------------

[Fig. 2](#F2){ref-type="fig"} shows changes from baseline for all 3 HRQoL outcomes for randomised patients with *BRAF* mutation (left) and *BRAF* wild type (right). A clinically meaningful decline was observed in the *BRAF* mutation subgroup with ipilimumab treatment at weeks 11 and 13 in the EQ-5D VAS and a clinically meaningful improvement in the *BRAF* wild-type subgroup for nivolumab at weeks 31--37. No other clinically meaningful changes were observed at any other time point.

Changes from baseline for all three HRQoL outcomes for randomised patients with either complete or partial response are shown in [Fig. 3](#F3){ref-type="fig"} (left). A clinically meaningful decline was observed with the ipilimumab treatment group for the EQ-5D VAS at week 19. No other clinically meaningful changes were observed.

Changes from baseline for all three HRQoL outcomes for randomised patients with a grade 3 or 4 AE are shown in [Fig. 3](#F3){ref-type="fig"} (right panels). Clinically meaningful declines were observed in the early weeks with ipilimumab in the EQ-5D VAS outcome and with nivolumab + ipilimumab in the EORTC QLQ-C30 at week 17. No other clinically meaningful changes were observed, although the nivolumab group had borderline improvement in the EQ-5D utility index from weeks 37--43.

[Fig. 4](#F4){ref-type="fig"} shows changes from baseline (last measurement before discontinuation) to follow-up visits 1 and 2 for all three HRQoL outcomes for patients who discontinued for any reason (left) or due to an AE (right). No clinically meaningful changes were observed in any of the three assessments for patients who discontinued for any reason. Due to low patient numbers in other groups of patients who discontinued due to an AE, conclusions can only be drawn for the nivolumab + ipilimumab group. For this group, a clinically meaningful decline was observed only inthe EQ-5D VAS assessment at follow-up visits 1 and 2.

3.5. HRQoL combined with response rate and grade 3/4 AEs {#S16}
--------------------------------------------------------

To observe response rate and grade 3/4 AEs with regard to HRQoL, we created an overlay of the randomised population EORTC QLQ-C30 with best overall response (BOR) at 6 months and 12 months for the 3 treatment groups, along with percentage of grade 3/4 AEs at 11 weeks, 6 months, and 12 months for the three treatment groups ([Fig. A.2](#SD1){ref-type="supplementary-material"}). Differences in BOR and grade 3/4 AEs between the arms do not seem to correlate with EORTC QLQ-C30.

4. Discussion {#S17}
=============

Nivolumab alone and combined with ipilimumab have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study, although the combination resulted in a higher frequency of grade 3/4 AEs \[[@R4]\]. Here we show that nivolumab + ipilimumab and nivolumab alone maintained HRQoL and no deterioration was observed over time compared with ipilimumab. In addition, similar results were observed across patient subgroups including *BRAF* mutation status, patients with complete and partial responses, and patients with grade 3 or 4 AEs over time. In the main scale analyses, no clinically meaningful changes were detected for either nivolumab or nivolumab + ipilimumab around the week 12 time point (first staging for these patients). In addition, no changes in HRQoL were observed during follow-up visits for patients who discontinued due to any cause; for patients who discontinued due to an AE, clinically meaningful declines were only observed for one of the three assessments.

Patient-focussed care is becoming a more critical component of quality health care \[[@R22]\]. Specifically, PROs are more prominent and were used in 27% of clinical trials registered from November 2007 to December 2013 \[[@R11]\]. Moreover, an initiative has been established to provide recommendations on analysis standardization of HRQoL and other PROs in randomised cancer trials \[[@R10]\].

Investigating HRQoL is important for immune checkpoint inhibitors because of the associated toxicity profile. In this study, HRQoL stayed within ranges defined as MID in the EORTC QLQ-C30, EQ-5D utility index, and EQ-5D VAS assessments, including across various subgroups of patients. HRQoL has also been better maintained by pembrolizumab than by chemotherapy in a phase II study in patients with ipilimumab-refractory melanoma \[[@R23]\]. Combined targeted therapy of BRAF inhibitors and mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2 (MEK) inhibitors is another treatment for advanced melanoma. The addition of trametinib to dabrafenib in a phase III trial in patients with metastatic melanoma and the *BRAF* V600 mutation did not result in patient deterioration of HRQoL and, in fact, improved EORTC QLQ-C30 scores compared with dabrafenib mono-therapy \[[@R24]\]. Similar results were observed in a phase III open-label trial for the combination of dabrafenib plus trametinib compared with vemurafenib in patients with *BRAF* V600 metastatic melanoma \[[@R25]\].

Of note, the marked difference in the rate of grade 3/4 AEs observed in the three arms (nivolumab + ipilimumab \[58.5%\], nivolumab \[20.8%\], and ipilimumab \[27.7%\] \[[@R6]\]) did not translate into a clinically meaningful difference in HRQoL. This may be due to several factors, for example, HRQoL may be driven by anxiety and willingness to survive at treatment start, thereby neutralising the negative perception of AEs. Also, the instruments used to assess HRQoL are designed for patients treated with chemotherapy and may not detect the impact of the AEs observed with immunotherapy. Lastly, patient numbers were low in both the later weeks of analysis, and within some of the subgroups analysed, thus limiting the interpretation of the results. Using these results, one could conclude that nivolumab + ipilimumab does not seem to be limited by HRQoL considerations, however, trial populations may differ from the 'real-world' patient with melanoma in terms of motivation, the likelihood of PRO reporting, and the ability to withstand treatment-related AEs.

Along with OS and PFS, quality-of-life measures have been included for use in the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) \[[@R26]\]. This scale, proposed to be a standardised validated approach to stratify the magnitude of clinical benefit anticipated from anticancer therapies, will be used to emphasise treatments in the ESMO guidelines. The CheckMate 067 study demonstrated improved efficacy, and has now shown stable HRQoL for multiple assessments.

In conclusion, HRQoL was maintained in all treatment groups with little clinically meaningful changes noted in EORTC QLQ-C30, EQ-5D utility index, and EQ-5D VAS assessments. Similar results were observed across patient subgroups including *BRAF* mutation status, patients with complete and partial responses, and patients with grade 3 or 4 AEs over time, as well as during follow-up visits for patients who discontinued due to any cause. These results further support the clinical benefit of nivolumab monotherapy and nivolumab + ipilimumab combination therapy over ipilimumab monotherapy in patients with advanced melanoma.
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![Change in baseline in HRQoL for total quality-of-life population. Mean (SD) EORTC QLQ-C30 global health score (A) at baseline was 74.7 (19.4) for nivolumab, 70.7 (22.3) for nivolumab + ipilimumab, and 73.5 (20.5) for ipilimumab; mean (SD) EQ-5D utility index score (B) at baseline was 0.803 (0.219) for nivolumab, 0.779 (0.234) for nivolumab + ipilimumab, and 0.791 (0.226) for ipilimumab; mean (SD) EQ-5D VAS score (C) at baseline was 75.9 (18.5) for nivolumab, 74.0 (19.9) for nivolumab + ipilimumab, and 75.8 (18.3) for ipilimumab. Clinical significance (denoted by the horizontal dashed line at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30, 0.8 points for EQ-5D utility index, and 7 points for EQ-5D VAS. SD, standard deviation.](nihms926889f1){#F1}

![Change in baseline in HRQoL for *BRAF* mutation status subgroup. Clinical significance (denoted by the horizontal dashed line at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30 (A, B), 0.8 points for EQ-5D utility index (C, D), and 7 points for EQ-5D VAS (E, F).](nihms926889f2){#F2}

![Change in baseline in HRQoL for patient response and AEs subgroups. Clinical significance (denoted by the horizontal dashed line at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30 (A, B), 0.8 points for EQ-5D utility index (C, D), and 7 points for EQ-5D VAS (E, F).](nihms926889f3){#F3}

![Change in baseline in HRQoL for patients who discontinued therapy for any cause or due to an AE. Clinical significance (denoted by the horizontal dashed line at these points) was determined by the MID value for each test, which was 10 points for EORTC QLQ-C30 (A, B), 0.8 points for EQ-5D utility index (C, D), and 7 points for EQ-5D VAS (E, F).](nihms926889f4){#F4}

###### 

Characteristics of patients at baseline.

                                         Patient-reported outcome population   Overall study \[[@R4]\]                               
  -------------------------------------- ------------------------------------- ------------------------- ------------- ------------- ------------
  Age                                                                                                                                
   Mean (SD)                             58.9 (13.2)                           59.2 (14.0)               60.7 (13.2)   59.6 (13.5)   60 (13.7)
  Sex, n (%)                                                                                                                         
   Male                                  173 (64.1)                            183 (66.8)                167 (64.5)    523 (65.1)    610 (64.6)
   Female                                97 (35.9)                             91 (33.2)                 92 (35.5)     280 (34.9)    335 (35.4)
  ECOG performance status score, n (%)                                                                                               
   0                                     209 (77.4)                            207 (75.5)                186 (71.8)    602 (75.0)    692 (73.2)
   ≥1                                    61 (22.6)                             67 (24.5)                 73 (28.2)     201 (25.0)    252 (26.7)
  Metastasis stage, n (%)                                                                                                            
   M0/M1a/M1b                            114 (42.2)                            116 (42.3)                111 (42.9)    341 (42.5)    397 (42.0)
   M1c                                   156 (57.8)                            158 (57.7)                148 (57.1)    462 (57.5)    548 (58.0)
  Lactate dehydrogenase status, n (%)                                                                                                
   ≤ULN                                  172 (63.7)                            181 (66.1)                167 (64.5)    520 (64.8)    589 (62.3)
   \>ULN                                 94 (34.8)                             93 (33.9)                 90 (34.7)     277 (34.5)    341 (36.1)
   Missing                               4 (1.5)                               0                         2 (0.8)       6 (0.7)       15 (1.6)
  Brain metastases, n (%)                                                                                                            
   Yes                                   6 (2.2)                               9 (3.3)                   9 (3.5)       24 (3.0)      34 (3.6)
   No                                    264 (97.8)                            265 (96.7)                250 (96.5)    779 (97.0)    911 (96.4)
  *BRAF* mutation status, n (%)                                                                                                      
   Mutation                              83 (30.7)                             93 (33.9)                 84 (32.4)     260 (32.4)    298 (31.5)
   Wild type                             187 (69.3)                            181 (66.1)                175 (67.6)    543 (67.6)    647 (68.5)
  PD-L1 status, n (%)                                                                                                                
   Positive                              126 (46.7)                            126 (46.0)                120 (46.3)    372 (46.3)    223 (23.6)
   Negative                              144 (53.3)                            148 (54.0)                139 (53.7)    431 (53.7)    620 (65.6)

Based on patients who had both baseline and at least one post-baseline HRQoL assessment.

ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; ULN, upper limit of normal.

###### 

Patient-reported outcome completion rates.[a](#TFN3){ref-type="table-fn"}

  Patients, n/N (%)                            Nivolumab (*n* = 316)   Nivolumab + ipilimumab (*n* = 314)   Ipilimumab (*n* = 315)
  -------------------------------------------- ----------------------- ------------------------------------ ------------------------
  **EORTC QLQ-C30**                                                                                         
  Baseline[b](#TFN4){ref-type="table-fn"}      284/316 (89.9)          290/314 (92.4)                       279/315 (88.6)
  Baseline plus ≥1                             269/316 (85.1)          274/314 (87.3)                       259/315 (82.2)
  Week 5                                       228/302 (75.5)          182/293 (62.1)                       220/300 (73.3)
  Week 7                                       237/291 (81.4)          182/276 (65.9)                       217/291 (74.6)
  Week 11                                      198/271 (73.1)          113/226 (50.0)                       163/244 (66.8)
  Week 13                                      193/249 (77.5)          106/201 (52.7)                       129/205 (62.9)
  Week 17                                      156/220 (70.9)          83/164 (50.6)                        103/158 (65.2)
  Week 19                                      164/205 (80.0)          97/155 (62.6)                        98/144 (68.1)
  Week 23                                      133/188 (70.7)          87/137 (63.5)                        76/118 (64.4)
  Week 25                                      142/182 (78.0)          97/130 (74.6)                        74/111 (66.7)
  Week 31                                      121/164 (73.8)          92/125 (73.6)                        50/87 (57.5)
  Week 37                                      112/152 (73.7)          90/119 (75.6)                        48/75 (64.0)
  Week 43                                      100/145 (69.0)          74/114 (64.9)                        44/65 (67.7)
  Week 49                                      92/128 (71.9)           65/97 (67.0)                         40/58 (69.0)
  Week 55                                      63/100 (63.0)           48/72 (66.7)                         24/43 (55.8)
  Week 61                                      38/58 (65.5)            29/42 (69.0)                         17/28 (60.7)
  Week 67                                      13/21 (61.9)            16/22 (72.7)                         9/13 (69.2)
  Week 73                                      3/4 (75.0)              6/9 (66.7)                           0/2 (0)
  Week 79                                      --                      2/2 (100.0)                          1/2 (50.0)
  Follow-up 1[c](#TFN5){ref-type="table-fn"}   96/104 (92.3)           105/108 (97.2)                       124/136 (91.2)
  Follow-up 2[c](#TFN5){ref-type="table-fn"}   58/62 (93.5)            96/99 (97.0)                         97/103 (94.2)
  **EQ-5D**                                                                                                 
  Baseline[b](#TFN4){ref-type="table-fn"}      282/316 (89.2)          290/314 (92.4)                       278/315 (88.3)
  Baseline plus ≥1                             267/316 (84.5)          274/314 (87.3)                       258/315 (81.9)
  Week 5                                       227/302 (75.2)          180/293 (61.4)                       218/300 (72.7)
  Week 7                                       237/291 (81.4)          182/276 (65.9)                       216/291 (74.2)
  Week 11                                      198/271 (73.1)          113/226 (50.0)                       163/244 (66.8)
  Week 13                                      193/249 (77.5)          106/201 (52.7)                       129/205 (62.9)
  Week 17                                      156/220 (70.9)          83/164 (50.6)                        103/158 (65.2)
  Week 19                                      163/205 (79.5)          97/155 (62.6)                        97/144 (67.4)
  Week 23                                      133/188 (70.7)          87/137 (63.5)                        76/118 (64.4)
  Week 25                                      142/182 (78.0)          97/130 (74.6)                        74/111 (66.7)
  Week 31                                      121/164 (73.8)          92/125 (73.6)                        50/87 (57.5)
  Week 37                                      112/152 (73.7)          89/119 (74.8)                        48/75 (64.0)
  Week 43                                      100/145 (69.0)          74/114 (64.9)                        44/65 (67.7)
  Week 49                                      92/128 (71.9)           65/97 (67.0)                         40/58 (69.0)
  Week 55                                      63/100 (63.0)           48/72 (66.7)                         24/43 (55.8)
  Week 61                                      38/58 (65.5)            29/42 (69.0)                         17/28 (60.7)
  Week 67                                      13/21 (61.9)            16/22 (72.7)                         9/13 (69.2)
  Week 73                                      3/4 (75.0)              6/9 (66.7)                           0/2 (0)
  Week 79                                      --                      2/2 (100.0)                          1/2 (50.0)
  Follow-up 1[c](#TFN5){ref-type="table-fn"}   96/104 (92.3)           105/108 (97.2)                       124/136 (91.2)
  Follow-up 2[c](#TFN5){ref-type="table-fn"}   58/62 (93.5)            96/99 (97.0)                         97/103 (94.2)

Completion rate is calculated using the number of patients with non-missing PRO data at baseline and data from ≥ 1 post-baseline visit, divided by the number of patients in the study at each respective time point.

Baseline completion rate based on subjects having any baseline data with no post-baseline data requirement.

Follow-up visit 1 = 30 d from the last dose (± 7 d) or coinciding with the date of discontinuation (±7 d) if date of discontinuation is greater than 37 d after last dose; follow-up visit 2 = 84 d (± 7 d) from follow-up visit 1.
